A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin ® ) in Healthy Male Subjects

ConclusionIn this study, BAT1706, a proposed biosimilar of BEV, was shown to be highly similar to EU-BEV and US-BEV in terms of pharmacokinetic equivalence, safety, and immunogenicity in healthy subjects  after a single IV infusion.Trial RegistrationNCT03030430.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research